抗生素联合治疗老年慢阻肺患者社区获得性肺炎的临床疗效分析

Analysis of Clinical Efficacy of Antibiotics Treating Senile Chronic Obstructive Pulmonary Disease Patients with Community Acquired Pneumonia

目的探讨阿莫西林/克拉维酸钾联合阿奇霉素治疗老年慢阻肺伴社区获得性肺炎患者的临床疗效及安全性。方法COPD伴社区获得性肺炎感染的老年患者按住院单双号顺序分为研究组和对照组各100例,研究组接受阿莫西林/克拉维酸钾联合阿奇霉素抗感染,对照组仅接受阿莫西林/克拉维酸钾抗感染,两组治疗方法均相同。对比研究组和对照组的治疗疗效、住院时间、住院费用及抗生素相关不良反应发生率。结果:两组治疗疗效、住院时间及住院费用差异有统计学意义(P<0.05);研究组和对照组抗生素相关不良反应发生率分别为9%、12%,差异无统计学意义(P>0.05)。结论:本次研究认为阿莫西林/克拉维酸钾联合阿奇霉素治疗老年慢阻肺伴社区获得性肺炎患者疗效肯定,使用安全。

Objective To discuss the clinical efficacy and safety of moxicillin/clavulanate potassium combined with azithromycin in treating senile chronic obstructive pulmonary disease patients with community acquired pneumonia. Methods 200 cases of COPD patients were divided into study group using amoxicillin/clavulanate potassium combined with azithromycin and control group using amoxicillin/clavulanate according to single and double order （100 cases each）. To compare therapeutic efficacy, hospitalization time, treatment costs and antibiotic related adverse reaction incidence rate were counted. Results There had statistical deffrence in therapeutic efficacy, hospitalization time and treatment costs （P〈0.05） between two groups. Antibiotic related adverse reaction incidence rate of study group and control group were respectively 9% and 12%, differences had no statistical significance （P〉0.05） . Conclusion The study considers that amoxicillin/clavulanate potassium combined with azithromycin in treating senile chronic obstructive pulmonary disease patients with community acquired pneumonia is curative effective and safely.